1. BSAVA Guide to the Use of Veterinary Medicines: Responsible Use of Antimicrobial Agents.


2. WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) 2011: Critically Important Antimicrobials for Human Medicine (3rd Revision)


3. Maddison JE. (2009) Making drug choices: rational antibacterial therapy. Irish Veterinary Journal 62:469-475


4. Rang HP, Dale MM, Ritter JM, & Moore PK. (2003) Pharmacology (Fifth Edition)


5. Ramsey I. (2008) British Small Animal Veterinary Association Small Animal Formulary Sixth Edition


6. National Office of Animal Health Compendium of Datasheets for Animal Medicines 2013


7. Argyle S. (2013) Responsible use of antibiotics. Veterinary Times 2013 Jan 7:6-7


8. Beco L, Guaguère E, Lorente Méndez C, Noli C, Nuttall T & Vroom M. (2013) Suggested guidelines for using systemic antimicrobials in bacterial skin infections (2): antimicrobial choice, treatment regimens and compliance. Veterinary Record 172:156-60


9. Marbocyl – Marbofloxacin Reference Book (1999)


10. Litster AL, Wu CC, & Constable PD. (2012) Comparison of the efficacy of amoxicillin-clavulanic acid, cefovecin, and doxycycline in the treatment of upper respiratory tract disease in cats housed in an animal shelter. Journal of the American Veterinary Medical Association 241(2):218-26


11. Dossin O, Gruet P & Thomas E. (1998) Comparative field evaluation of marbofloxacin tablets in the treatment of feline upper respiratory infections. The Journal of Small Animal Practice 39(6):286-9


12. Veir JK, Ruch-Gallie R, Spindel ME & Lappin MR. (2008) Prevalence of selected infectious organisms and comparison of two anatomic sampling sites in shelter cats with upper respiratory tract disease. Journal of Feline Medicine and Surgery 10(6):551-7


13. Helps CR, Lait P, Damhuis A, Björnehammar U, Bolta D, Brovida C, Chabanne L, Egberink H, Ferrand G, Fontbonne A, Pennisi MG, Gruffydd-Jones T, Gunn-Moore D, Hartmann K, Lutz H, Malandain E, Möstl K, Stengel C, Harbour DA & Graat EA. (2005) Factors associated with upper respiratory tract disease caused by feline herpesvirus, feline calicivirus, Chlamydophila felis and Bordetella bronchiseptica in cats: experience from 218 European catteries. The Veterinary Record 156(21):669-73


14. Bovens C. (2013) Therapeutics in canine GI disorders: part two – treatment of diarrhoea. Veterinary Times 2013 Aug 5:10-11


15. Smith J. (2008) Canine prostatic disease: A review of anatomy, pathology, diagnosis, and treatment. Theriogenology 70:375-83


16. Weese JS, Blondeau JM, Boothe D, Breitschwerdt EB, Guardabassi L, Hillier A, Lloyd DH, Papich MG, Rankin SC,Turnidge JD & Sykes JE. (2011) Antimicrobial Use Guidelines for Treatment of Urinary Tract Disease in Dogs and Cats: Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases. Veterinary Medicine International 2011:263768


17. Summersgill JT, Schupp LG & Raff MJ. (1982) Comparative Penetration of Metronidazole, Clindamycin, Chloramphenicol, Cefoxitin, Ticarcillin, and Moxalactam into Bone. Antimicrobial Agents and Chemotherapy 21(4):601-3


18. Daly CR, Fitzgerald Jnr RH & Washington II JA. (1982) Penetration of Cefazolin into Normal and Osteomyelitic Canine Cortical Bone. Antimicrobial Agents and Chemotherapy 22(3):461-9


19. Darley ESR and MacGowan AP. (2004) Antibiotic treatment of Gram-positive bone and joint infections. Journal of Antimicrobial Chemotherapy 53:928-35


20. Bugden DL. (2013) Identification and antibiotic susceptibility of bacterial isolates from dogs with otitis externa in Australia. Australian Veterinary Journal 91(1-2):43-6


21. Kohanski MA, Dwyer JG & Collin JJ. (2010) How antibiotics kill bacteria: from targets to networks. Nature Reviews Microbiology 8(6):423-35


22. Jacobs MR. (2001) Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clinical Microbiology and Infection 7:589-96


23. McKellar QA, Sanchez Bruni SF & Jones DG. (2004) Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics 27:503–14


24. Küng K and Wanner M. (1994) Bioavailability of different forms of amoxycillin administered orally to dogs. The Veterinary Record 135(23):552-4


25. Plumb DC. (2005) Plumb’s Veterinary Drug Handbook (Fifth Edition)


26. Vree TB, Dammers E & Van Duuren E. (2003) Variable absorption of clavulanic acid after an oral dose of 25 mg/kg of Clavubactin and Synulox in healthy dogs. Journal of Veterinary Pharmacology and Therapeutics 26(3):165-71


27. Vree TB, Dammers E & Van Duuren E. (2002) Variable Absorption of Clavulanic Acid After an Oral Dose of 25 mg/kg of Clavubactin® and Synulox® in Healthy Cats The Scientific World Journal 2:1369–1378


28. Papich MG, Davis JL & Floerchinger AM. (2010) Pharmacokinetics, protein binding, and tissue distribution of orally administered cefpodoxime proxetil and cephalexin in dogs. American Journal of Veterinary Research 71(12):1484-91


29. Vilmànyi E, Küng K, Riond JL, Trümpi B & Wanner M. (1996) Clarithromycin pharmacokinetics after oral administration with or without fasting in crossbred beagles. The Journal of Small Animal Practice 37(11):535-9


30. Batzias GC, Delis GA & Athanasiou LV. (2005) Clindamycin bioavailability and pharmacokinetics following oral administration of clindamycin hydrochloride capsules in dogs. The Veterinary Journal 170:339–345


31. Lees P. (2013) Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat. Journal of Veterinary Pharmacology and Therapeutics 36:209-21


32. Heinen E. (2002) Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. Journal of Veterinary Pharmacology and Therapeutics 25(1):1-5


33. Albarellos G, Montoya L, Ambros L, Kreil V, Hallu R & Rebuelto M. (2004) Multiple once-daily dose pharmacokinetics and renal safety of gentamicin in dogs. Journal of Veterinary Pharmacology and Therapeutics 27(1):21-5


34. Guardabassi L. (2012) Veterinary hospital-acquired infections: The challenge of MRSA and other multidrug-resistant bacterial infections in veterinary medicine.The Veterinary Journal 193:307-8


35. Johnson JA. (2002) Nosocomial infections. The Veterinary Clinics Small Animal Practice 32:1101-26


36. Benedict KM, Morley PS & Van Metre DC. (2008) Characteristics of biosecurity and infection control programs at veterinary teaching hospitals. Journal of the American Veterinary Medical Association 233(5):767-73


37. Schott HC, Ewart SL, Walker RD, Dwyer RM, Dietrich S, Eberhart SW, Kusey J, Stick JA & Derksen FJ. (2001) An outbreak of salmonellosis among horses at a veterinary teaching hospital. Journal of the American Veterinary Medical Association 218(7):1152-9


38. Morley PS. (2013) Evidence-Based Infection Control In Clinical Practice: If You Buy Clothes for the Emperor, Will He Wear Them? Journal of Veterinary Internal Medicine 27:430-8


39. De Man P, van der Veeke E, Leemreijze M, van Leeuwen W, Vos G, van den Anker J, Verbrugh H & van Belkum A. (2001) Enterobacter Species in a Pediatric Hospital: Horizontal Transfer or Selection in Individual Patients? The Journal of Infectious Diseases 184(2):211-4


40. Seguin JC, Walker DR, Caron JP, Cloos WE, George CG, Hollis RJ, Jones RN & Pfaller MA. (1999) Methicillin-Resistant Staphylococcus aureus Outbreak in a Veterinary Teaching Hospital: Potential Human-to-Animal Transmission Journal of Clinical Microbiology 37(5):1459-63


41. BSAVA practice guidelines – reducing the risk from MRSA and MRSP. Accessed August 2013


42. FECAVA Key Recommendations for Hygiene and Infection Control in Veterinary Practice.


43. Veterinary Nurse Training Online: Correct Hand Washing Technique. Accessed August 2013


44. Wesche P, Naylor PF & Wray C. (2005) Sanitisation, disinfection and sterilisation in veterinary practice. Veterinary Review Oct 2005:32-3


45. The Center for Food Security and Public Health: Characteristics of Selected Disinfectants (2008). Accessed August 2013


46. WHO Europe. Accessed August 2013


47. BBC News Health (03/06/2011) MRSA: New strain of superbug found in cows. Accessed August 2013.


48. Aldeyab MA, Harbarth S, Vernaz N, Kearney MP, Scott GM, Darwish Elhajji FW, Aldlab MA & McElnay JC. (2011) The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. British Journal of Clinical Pharmacology 74(1):171-9


49. Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, Johnson AP, Pike R, Warner M, Cheasty T, Pearson A, Harry S, Leach JB, Loughrey A, Lowes JA, Warren R.E & Livermore DM. (2004) Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. Journal of Antimicrobial Chemotherapy 54: 735-743


50. Isendahl J, Turlej-Rogacka A, Manjuba C, Rodrigues A, Giske CG & Nauclér P. (2012) Fecal Carriage of ESBL-producing E. coli and K. pneumoniae in Children in Guinea-Bissau: A Hospital-Based Cross-Sectional Study. PLoS One 7(12):e51981


51. Rushdy AA, Mabrouk MI, Abu-Sef FA, Kheiralla ZH, -All SM & Saleh NM. (2013) Contribution of different mechanisms to the resistance to fluoroquinolones in clinical isolates of Salmonella enterica. Brazilian Journal of Infectious Diseases 17(4):431-7


52. Leclercq R. (2002) Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clinical Infectious Diseases 34(4):482-92


53. Kaplan E, Ofek M, Jurkevitch E & Cytryn E. (2013) Characterization of fluoroquinolone resistance and qnr diversity in Enterobacteriaceae from municipal biosolids.   Frontiers in Microbiology 4:144


54. Rice LB. (2012) Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones. Mayo Clinic Proceedings 87(2):198-208


55. Shi K, Caldwell SJ, Fong DH & Berghuis AM. (2013) Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance.   Frontiers in Cellular and Infection Microbiology 3:22


56. Roberts MC. (2005) Update on acquired tetracycline resistance genes. FEMS Microbiology Letters 245(2):195-203


57. Costa SS, Viveiros M, Amaral L & Couto I. (2013) Multidrug Efflux Pumps in Staphylococcus aureus: an Update. The Open Microbiology Journal 7:59-71


58. Haasum Y, Ström K, Wehelie R, Luna V, Roberts MC, Maskell JP, Hall LM & Swedberg G. (2001) Amino Acid Repetitions in the Dihydropteroate Synthase of Streptococcus pneumoniae Lead to Sulfonamide Resistance with Limited Effects on Substrate Km. Antimicrobial Agents in Chemotherapy 45(3):805-9


59. Leverstein-van Hall MA, M Blok HE, T Donders AR, Paauw A, Fluit AC & Verhoef J. (2003) Multidrug Resistance among Enterobacteriaceae Is Strongly Associated with the Presence of Integrons and Is Independent of Species or Isolate Origin. The Journal of Infectious Diseases 187(2):251-9


60. Dahshan H, Shahada F, Chuma T, Moriki H & Okamoto K. (2010) Genetic analysis of multidrug-resistant Salmonella enterica serovars Stanley and Typhimurium from cattle. Veterinary Microbiology 145:76–83


61. WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) 2011: Critically Important Antimicrobials for Human Medicine (3rd Revision)


62. Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM & Baddour LM. (2006) The Impact of Penicillin Resistance on Short-Term Mortality in Hospitalized Adults with Pneumococcal Pneumonia: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases 42(6):788-97


63. Kim T, Oh PI, Simor AE. (2001) The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infection Control and Hospital Epidemiology 22(2):99-104


64. Jeffers JG. (2013) Topical Therapy for Drug-Resistant Pyoderma in Small Animals. Veterinary Clinics of North America Small Animal Practice 43:41–50


65. Haenni M, Ponsin C, Métayer V, Médaille C & Madec JY. (2012) Veterinary hospital-acquired infections in pets with a ciprofloxacin-resistant CTX-M-15-producing Klebsiella pneumoniae ST15 clone. Journal of Antimicrobial Chemotherapy 67(3):770-1


66. Tetsuo A, Kojima A, Harada K, Ishihara K, Takahashi T & Tamura Y. (2005) Correlation between the Usage Volume of Veterinary Therapeutic Antimicrobials and Resistance In Escherichia coli Isolated from the Feces of Food-Producing Animals in Japan. Japanese Journal of Infectious Diseases 58:369-72


67. Aarestrup FM, Agerso Y, Gerner-Smidt P, Madsen M, Jensen LB. (2000) Comparison of antimicrobial resistance phenotypes and resistance genes in Enterococcus faecalis and Enterococcus faecium from humans in the community, broilers, and pigs in Denmark. Diagnostic Microbiology and Infectious Disease 37(2):127-37


68. Singer RS, Patterson SK & Wallace RL. (2008) Effects of Therapeutic Ceftiofur Administration to Dairy Cattle on Escherichia coli Dynamics in the Intestinal Tract. Applied and Environmental Microbiology 74(22):6956-62


69. Walther B, Hermes J, Cuny C, Wieler LH, Vincze S, Abou Elnaga Y, Stamm I, Kopp PA, Kohn B, Witte W, Jansen A, Conraths FJ, Semmler T, Eckmanns T & Lübke-Becker A. (2012) Sharing More than Friendship – Nasal Colonization with Coagulase-Positive Staphylococci (CPS) and Co-Habitation Aspects of Dogs and Their Owners. PLoS One 7(4):e35197


70. Martins LR, Pina SM, Simões RL, de Matos AJ, Rodrigues P & da Costa PM. (2013) Common phenotypic and genotypic antimicrobial resistance patterns found in a case study of multiresistant E. Coli from cohabitant pets, humans, and household surfaces. Journal of Envrionmental Health 75(6):74-81


71. Ferreira JP, Anderson KL, Correa MT, Lyman R, Ruffin F, Reller LB & Fowler VG Jr. (2011) Transmission of MRSA between Companion Animals and Infected Human Patients Presenting to Outpatient Medical Care Facilities. PLoS One 6(11):e26978


72. Kataoka Y, Ito C, Kawashima A, Ishii M, Yamashiro S, Harada K, Ochi H & Sawada T. (2013) Identification and Antimicrobial Susceptibility of Enterococci Isolated from Dogs and Cats Subjected to Differing Antibiotic Pressures. The Journal of Veterinary Medical Science 75(6):749-53


73. One Health Initiative: Mission Statement Accessed August 2013


74. Zeng X and Lin J. (2013) Beta-lactamase induction and cell wall metabolism in Gram-negative bacteria. Frontiers in Microbiology 4:128


75. Li W, Atkinson GC, Thakor NS, Allas U, Lu CC, Chan KY, Tenson T, Schulten K, Wilson KS, Hauryliuk V & Frank J. (2013) Mechanism of tetracycline resistance by ribosomal protection protein Tet(O). Nature Communications 4:1477


76. Then RL. (1982) Mechanisms of resistance to trimethoprim, the sulfonamides, and trimethoprim-sulfamethoxazole. Reviews of Infectious Diseases 4(2):261-9


77. Mactaggart D. (2008) Assessment and management of chronic ear disease. In Practice 30:450-8


78. Scott DW, Miller Jr WH & Griffin CE. (2001) Muller & Kirk’s Small Animal Dermatology. Sixth Edition


79. National Office for Animal Health (NOAH) Antibiotics for Animals Briefing Documents. Accessed August 2013


80. Mather AE, Matthews L, Mellor DJ, Reeve R, Denwood MJ, Boerlin P, Reid-Smith RJ, Brown DJ, Coia JE, Browning LM, Haydon DT & Reid SW. (2012) An ecological approach to assessing the epidemiology of antimicrobial resistance in animal and human populations. Proceedings. Biological Sciences 279(1733):1630-9


81. Westermarck E, Skrzypczak T, Harmoinen J, Steiner JM, Ruaux CG, Williams DA, Eerola E, Sundbäck P & Rinkinen M. (2005) Tylosin-responsive chronic diarrhea in dogs. Journal of Veterinary Internal Medicine 19(2):177-86


82. Hostutler RA, Luria BJ, Johnson SE, Weisbrode SE, Sherding RG, Jaeger JQ & Guilford WG. (2004) Antibiotic-responsive histioctic ulcerative colitis in 9 dogs. Journal of Veterinary Internal Medicine 18(4):499-504


83. British Small Animal Veterinary Association (BSAVA) (2011) PROTECT poster: Are you protecting your antibacterials? Updated March 2012


84. Hale FA. (2012) Antibiotic Use in Veterinary Dentistry. Accessed August 2013


85. Riviere JE & Papich MG. (2009) Veterinary Pharmacology and Therapeutics. Ninth Edition


86. Vétoquinol France. (2008) Doxyseptin summary of product characteristics





Disclaimer:  Indications and doses may vary between products.  The antimicrobials listed may constitute an off licence use of the product and as such should only be used according to the ‘Cascade’, further details of which are available on the RCVS, VMD and NOAH websites.  Veterinary surgeons are advised to carefully check the Summary of Product Characteristics (SPC) before prescribing a product and obtain informed owner consent where required.